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ABBREVATIONS 
CBA, cytometric bead array 
CFSE, carboxyfluorescein succinimidyl ester 
CMV, cytomegalovirus 
CTL, cytotoxic T lymphocytes 
+donor, seropositive donor 
EBV, Epstein-Barr virus 
FACS, fluorescence-activated cell sorting 
GvH, graft-versus-host 
GvHD, graft-versus-host disease 
GvHR, graft-versus-host reaction 
HLA, human leukocyte antigen 
Hour, h 
HSCT, haematopoietic stem cell transplantation 
IE-1, immediate early protein-1 
IFN-ϒ, interferon-gamma 
IFN-ϒ secretion assay, gamma catch 
ml, millilitres 
MLR, mixed lymphocytes reaction 
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PBMC, peripheral blood mononuclear cell 
PHA, phytohaemagglutinin 
pp65, phosphoprotein 65 
SDC, supplementary digital content 
SEM, standard error of the mean 
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ABSTRACT 
Background 
Graft-versus-host disease (GvHD) remains a serious concern for patients 
undergoing anti-viral cellular therapy. Despite the major improvements in cellular 
immunotherapy, the immunogenicity of virus-specific T-cells has not yet been 
fully defined. This present study aims to examine how cytomegalovirus (CMV)-
specific cytotoxic T-lymphocytes (CTLs) respond to allogeneic antigen stimulation 
and whether they give rise to GvHD-target-tissue damage. 
Methods 
CMV-CTLs were isolated by the interferon-gamma (IFN-ϒ) secretion assay 
(gamma-catch) from healthy seropositive volunteers and expanded in-vitro. The 
levels of intracellular IFN-ϒ, cytotoxic activity, IFN-ϒ and granzyme B secretion 
and CD25 expression were measured using flow cytometry (FACS). The ability of 
CMV-CTLs to induce GvHD-target-tissue damage was evaluated using the 
human in-vitro skin explant assay (skin explant assay). 
Results 
CMV-CTLs responded specifically to CMV-phosphoprotein 65 (pp65)-stimulation 
by secreting IFN-ϒ and killing virus peptide loaded autologous 
phytohaemagglutinin-blasts (PHA-blasts). Compared to unselected-PBMCs, 
CMV-CTLs induced significantly less severe cutaneous GvH-tissue damage. This 
observation coincided with low levels of CD25 expression, as well as IFN-ϒ and 
granzyme B secretion following allogeneic antigen stimulation in both the mixed 
lymphocyte reaction (MLR) and in the skin explant assay. 
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Conclusions  
CMV-CTLs isolated by the IFN-ϒ secretion assay from HLA-unmatched healthy 
donors exhibited a high level of anti-CMV potency without inducing significant 
cutaneous GvH-tissue damage in-vitro. This finding provides novel evidence 
supporting the safe use of in-vitro expanded CMV-CTLs as an anti-viral therapy 
in transplant patients with refractory CMV infections. 
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INTRODUCTION 
Haematopoietic stem cell transplantation (HSCT) represents a treatment for 
malignant and non-malignant blood disorders. Despite considerable success, 
application is limited due to graft-versus-host disease (GvHD)1. Conditioning regimen 
before transplant, increased immunosuppression to prevent/treat GvHD and other 
risk factors (age, human leukocyte antigen (HLA)-disparity, previous infections) delay 
the post-transplant immune reconstitution leading to latent-virus reactivation, adding 
to morbidity and mortality2,3. 
CMV is a common β-herpesvirus, between 30% and 90% in the occidental 
population4,5. In immunocompetent individuals, CMV infection is unproblematic. 
However it can reactivate in 20-30% of immunocompromised patients undergoing 
HSCT hence affecting the overall survival6. CMV-serostatus of donor-recipient pairs 
is one of the major risk factors for CMV reactivation or de novo infection. The worst 
case scenario of CMV reactivation/infection is when seropositive patients are 
transplanted from seronegative donors or viceversa7.  
Pre-emptive therapy with anti-viral drugs, for viral infections in post-HSCT patients, is 
often not sufficient due to drug-resistance8 and toxicity9,10. Adoptive immuno-therapy 
for the restoration of anti-viral immunity, pioneered by Riddell and colleagues11, has 
been considered an alternative treatment for patients with refractory viral infections 
after failure of standard therapies. Several reports have demonstrated that adoptive 
virus-CTLs can successfully reconstitute cellular anti-viral immunity by reducing the 
viral load and even the severity of virus disease in HLA-matched and -mismatched 
transplant recipients12,13. Despite these promising results, de novo or exacerbated 
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GvHD remains a potential risk associated with the adoptive cellular therapy in 
(un)related mismatched transplant recipients.  
In the last two decades, the purity of isolated virus-specific CTLs has improved 
encouragingly14,15,16, thus potentially minimizing the risk of alloreactive GvHD. Most 
clinical trials have reported the reconstitution of anti-viral immunity after adoptive 
transfer of CMV-CTLs without major complications, although small subgroups of 
patients had onset or aggravation of pre-existing GvHD17,18,19,20,21. Surprisingly, no 
correlation between the cell dose and the success of anti-viral immune-reconstitution 
has been observed22,20. Very low doses of anti-Epstein-Barr virus (EBV) specific T-
cells, such as 148 CD3+ T-cell/kg, have been reported to efficiently clear the 
viremia23. These results suggest that increasing the purity of anti-viral T-cells and 
reducing the cell-dose might abrogate the onset of GvHD while restoring the anti-
viral immunity.  
Despite the low incidence of GvHD after adoptive virus-CTL therapy, several in-vitro 
studies have reported a broad allo-HLA-cross-reactivity of memory virus-CTLs24,25,26. 
Amir and colleagues reported that virus-CTL lines or clones (CMV, EBV, varicella 
zoster and influenza virus) were cross-reactive with a large panel of EBV-
transformed B-cell lines transduced with allo-HLA molecules. In addition, virus-
specific T-cells showed cross-reactivity against allo-HLA antigens expressed by 
normal B-cells, T-cells, dendritic or endothelial cells and fibroblasts, suggesting a 
potential in-vivo alloreactivity27,26. It has also been suggested that cross-reactivity 
may be tissue-specific due to differences in self-peptide antigen presentation by the 
allo-HLA-molecules on specific target-organs24,28.  
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Cross-reactivity of virus-CTLs for transfusion has also been reported by Melenhorst 
and colleagues, but patients who received adoptive transfusion of in-vitro cross-
reactive bi-virus-specific T-cell lines had no clinical GvHD, suggesting no correlation 
between in-vitro alloreactivity and the clinical outcome29. In addition, virus-specific T-
cells isolated by gamma-catch, together with a short-period of in-vitro expansion, 
showed less alloreactivity in the MLR when compared to unmanipulated donor 
lymphocytes30,31. Collectively these data may support the low immunogenicity of 
adoptive viral-specific T-cells and a disassociation between in-vitro tests and the 
clinical GvHD outcome. 
The present study investigates whether CMV-CTLs, isolated by gamma-catch, are 
able to mediate GvH-tissue damage using an unique human in-vitro GvHD skin 
explant model which has been used to predict GvHD in HLA-matched siblings32. The 
skin explant assay has been successfully used to demonstrate the specificity of 
minor histocompatibility antigen-specific cytotoxic T-cells33 and more recently to 
investigate the mechanisms of action of regulatory T-cells for the prevention of 
GvHD34,35. Here we provide the first in-vitro evidence demonstrating the severity of 
pathological changes in GvHD-target-tissue mediated by CMV-CTLs. 
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MATERIALS AND METHODS 
Samples 
Sixty millilitres (ml) of peripheral blood was collected from CMV-seropositive donors 
(CMV+donor) for the isolation of CMV-CTLs. Blood and skin for the skin explant 
assay was obtained from healthy volunteers. All donors were recruited by a research 
nurse with informed consent and approval by the Local Research Ethics Committee. 
Isolation of CMV-CTLs by gamma-catch  
Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient 
centrifugation. PBMCs were stimulated in-vitro with the pp65 protein of human CMV 
(PepTivator® CMV pp65-premium grade, Miltenyi Biotec, Bergisch Gladbach, 
Germany) at a concentration of 1µg/ml and incubated for 4 hours (h) at 37◦C and 5% 
CO2. Cells were then collected and processed as per manufacturer’s instructions 
(Large Scale IFN-ϒ Secretion Assay Enrichment Kit, Miltenyi). Briefly, in-vitro 
stimulated PBMCs were incubated for 5 minutes with IFN-ϒ Catchmatrix Reagent 
and then incubated for 45 minutes at 37◦C in a humidified incubator under slow 
rotation to allow the secretion of IFN-ϒ. Subsequently, cells were treated with anti-
IFN-ϒ micro-beads for magnetic separation by using a manual MidiMACS® 
Separator and LS separation column (Miltenyi). Unstimulated cells served as the 
negative controls. 
FACS 
The purity, specificity, functionality and potential alloreactivity of isolated and in-vitro 
expanded CMV-CTLs were assessed by FACS. Cells were stained following 
standard protocols and manufacturer’s instructions (Inside Stain Kit, Miltenyi). FACS 
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data were acquired on the BD FACS Canto II cytometer. Where possible, at least 
100,000 cells were recorded and analysed by FlowJo v10 software (Tree Start). The 
following antibodies were used (all obtained from BD Biosciences, Oxford, UK, 
unless otherwise indicated): CD45 (APC), CD3 (V450), CD4 (FITC), CD8 
(PercpCy5.5), CD14 (APC-CyTm7), IFN-ϒ (PE) (Miltenyi), CD4 (APC), CD25 (PE), 
CFSE (carboxyfluorescein-succinimidyl-ester, Life Technologies, Paisley, UK) and 
LIVE/DEAD® Aqua Stain (Life Technologies).  
In-vitro expansion of CMV-CTLs 
CMV-CTLs were expanded in-vitro for 2-4 weeks. All eluted cells were co-cultured 
with irradiated autologous feeder cells (20Gy) at a ratio of 1:100 and 250 IU/ml of IL-
2 (Miltenyi). The medium was replaced every 2-3 days. At the end of each week, 
cells were counted and subcultured as appropriate. After expansion, IL-2 was 
removed and cells were frozen until required for the experiments. 
The intracellular IFN-Y expression in expanded CMV-CTLs  
CMV-CTLs were plated at a density of 1.5x106/150 µl of medium and re-stimulated 
with pp65 (1µg/ml) for 2h. Unstimulated cells were used as the control. Brefaldin A 
(1µg/ml, BioLegend, London, UK) was then added and cells were incubated for an 
additional 4h. After a total incubation time of 6h, cells were harvested, attained and 
data were acquired by FACS. 
Cytotoxicity Assay  
CTL activity was evaluated by a CFSE-based cytotoxicity assay, slightly modified 
from that previously described36. Briefly, blast target cells were generated by 
stimulation of autologous PBMCs with 5µg/ml of phytohaemagglutinin (PHA, Sigma-
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Aldrich, Dorset, UK) for 5 days. Medium was then replenished every 2-3 days for 2 
weeks and IL-2 (100 IU/ml) was added. CD4+ PHA-blasts were isolated by magnetic 
separation (Miltenyi) and stimulated overnight with pp65 (5µg/ml), whereas 
unstimulated PHA-blasts were the unloaded control. PHA-blasts (loaded and 
unloaded) were then stained with CFSE 3 µM and plated at a density of 5x105 
cells/ml per well. CTLs were incubated with PHA-blasts at 20:1, 5:1 and 1:1 ratios for 
4h at 37◦C, 5% CO2. Cells were then collected and stained with appropriate 
antibodies and viability dye. Stained cells were transferred into TruCountTM Tubes 
(BD) containing a fixed amount of beads to allow the quantitative analyses of the T-
cell populations and data were acquired by FACS. Each experiment was performed 
in duplicate or triplicate and the percentage of specific lyses was calculated as 
follows: % of lysis= 100-(absolute no. of viable CFSE+ target cells (t=x)/absolute no. 
of viable CFSE+ target T-cells (t=0))*100 where t=x is the number of viable CFSE+ 
target cells in the presence of effector cells and t=0 is the number of viable CFSE+ 
target T-cells in the absence of effector cells. 
MLR and expression of CD25 activation marker 
CMV-CTLs or unselected PBMCs from the same CMV+donor were incubated in a 
MLR with an equal number of previously irradiated (20Gy) allogeneic PBMCs from a 
HLA-mismatched donor (stimulator), at a density of 2x106 cells/ml, in T25-flasks. 
After 7 days of co-culture, cells were collected and the CD25 activation marker was 
investigated by FACS. 
Skin explant assay  
The skin explant assay was originally described by Vogelsang and colleagues37 and 
subsequently revised by Dickinson et al.32 We investigated the potential of CMV-
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CTLs to elicit GvHR in HLA-mismatched individuals and compared the results to 
those obtained with unselected-PBMCs from the same CMV+donor. Briefly, virus-
CTLs or unselected-PBMCs were incubated in a MLR with an identical number of 
irradiated stimulator PBMCs. After 7 days, CMV-CTLs and unselected-PBMCs were 
washed and co-incubated with the recipient’s skin-tissue. 72h later the skin biopsies 
were collected and assessed for histopathological damage. The grading was 
performed according to Lerner’s criteria38 (I-IV): grade-I GvHR: mild vacuolization of 
basal cells (background); grade-II-IV reactions: positive for GvHR, giving rise to 
diffused vacuolization of basal cells with scattered dyskeratotic bodies in the 
epidermal layer (grade-II), subepidermal cleft formation (grade-III) and complete 
separation of the epidermal and dermal layer (grade-IV) (Figure 1). 
HLA genotyping for virus epitopes 
The genotyping for 12 potential virus-HLA restrictions (A*01:01, A*02:01, A*11:01, 
A*24:02; B*07:02, B*44:03, B*44:02, B*40:01, B*35:01, B*35:02, DRB1*01:01) was 
performed by PCR-SSOP at the NHS Blood and Transplant Centre, Newcastle Upon 
Tyne. 
IFN-ϒ and granzyme B detection  
The levels of IFN-ϒ and granzyme B in the supernatants of the skin explant assay 
were quantified using the Cytometric Bead Array (CBA) Kit (BD) following the 
manufacturer’s instructions. Data were analysed with FCAP Array Software (BD). 
Statistical analysis 
Statistical analyses were performed using paired and unpaired Student’s t-test 
(GraphPad Prism 5). The results were reported as median or mean ±standard error 
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of the mean (SEM). Correlation studies were performed using Spearman’s test (non-
parametric correlation) and Chi-Square Fisher's test (SPSS-Statistics v.21). 
Differences were considered significant with a P⩽0.05. 
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RESULTS 
Isolation and in-vitro expansion of CMV-CTLs 
CMV-CTLs were successfully isolated from 20 healthy CMV+donor by gamma-catch. 
For each isolation experiment, unstimulated-PBMCs were included as a negative 
control and FACS analysis was used to assess the purity of the separation. The pre-
selection frequency of CMV-CTLs secreting IFN-ϒ after pp65-antigen specific 
stimulation was 1.60% (mean; ±0.58%) for CD3+ T-cells, 0.78% (mean; ±0.19%) for 
CD4+ T-cells and 2.10% (mean; ±0.92%) for CD8+ T-cells (data not shown). After 
enrichment, a mean yield of 3.66x105 (±0.96) cells was obtained (data not shown) 
and the purity of CMV-CTLs was increased to 69.07% (±5.96%) for CD3+, 67.28% 
(±5.79%) for CD4+ and 68.02% (±7.07%) for CD8+ T-cells (Figure 2-A+supplemental 
digital data (SDC)-Figure 1) with no difference in the ratio between CD4+ or CD8+ T-
cell populations (data not shown). To investigate the potential allo-reactivity of CMV-
CTLs by the skin explant assay, the cells were expanded in-vitro for 2 to 4 weeks 
giving rise to a 235.80 (±82.43) fold increase (Figure 2-B). The CD8+ population 
expanded to a significantly greater extent (P=0.004). The total number of CD4+ and 
CD8+ CMV-CTLs after expansion was 3.65x106 (±1.25x106) and 1.55x107 
(±3.51x106), respectively (Figure 2-C). 
In-vitro expanded CMV-CTLs exhibited antigen-specific cytotoxicity 
Following in-vitro expansion, the percentage of T-cells responding to CMVpp65 
stimulation remained similar, except for the CD4+ T-cell population. After short term 
re-stimulation with the pp65-antigen, the frequency of CMV-CTLs measured by 
intracellular IFN-ϒ staining was 52.98% (±6.17%) for the CD3+ and 66.86% (±5.18%) 
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for the CD8+, while the CD4+ T-cells decreased to 32.81% (±5.27) (Figure 3-A+SDC-
Figure 2). 
The capacity of CMV-CTLs to kill target-cells presenting the viral antigen was further 
demonstrated by a CFSE-based cytotoxicity assay, where CTLs were incubated 
together with autologous PHA-blasts, with or without pp65. Expanded CMV-CTLs 
could specifically lyse autologous PHA-blasts presenting the pp65-antigen in a dose 
dependent manner (P=0.0079, P=0.0459 and P=0.07 for effector:target ratios of 20:1, 
5:1 and 1:1) (Figure 3-B+SDC-Figure 3). 
CMV-CTLs showed a low level of activation by allogeneic-antigens 
CMV-CTLs were examined for CD25 expression after stimulation with allogeneic-
PBMCs in a MLR (n=5). CMV-CTLs showed a significantly reduced CD25 allo-
activation compared to the respective unselected-PBMCs from the same 
CMV+donors in all T-cell populations (P<0.0001, P<0.004 and P<0.0002 for CD3+, 
CD4+ and CD8+ T-cells, respectively) (Figure 4+SDC-Figure 4). 
CMV-CTLs showed reduced in-vitro GvHR 
CMV-CTLs and the allo-unselected-PBMCs from the same individual were tested as 
a third party donor at a low (5x105) and a high (1x106) cell dose in the skin explant 
assay for GvHR activity (n=9). As a positive control, skin was co-cultured with allo-
unselected-PBMCs (5x105) from HLA-unmatched CMV-+donor. This led to grade-II 
and -III GvHR. In contrast, using the corresponding CMV-CTLs (5x105), all skin 
sections demonstrated grade-I background GvHR. The difference in the 
histopathology grade between allo-unselected-PBMCs and CMV-CTLs was 
statistically significant (P<0.0006). Skin co-cultured with the high cell dose (1x106) of 
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allo-unselected-PBMCs resulted in grade-II, -III and -IV GvHR in the skin explant 
assays, whereas the corresponding high cell dose of CMV-CTLs showed 
significantly less severe GvHR (P<0.0001) with 7/9 CMV-CTLs showing a grade-I 
background reaction and two CMV-specific T-cell lines (donor 6 and 8) a mild grade-
II response (Figure 5, A). There was no correlation between the purity of CMV-CTLs 
after expansion and the skin histopathology grading (data not shown).  
In clinical protocols, adoptive immunotherapy is considered feasible if virus-specific 
T-cells are matched to the recipient for at least one HLA-allele with confirmed anti-
viral activity39. Shared HLA-alleles in donor-recipient pairs were analysed 
retrospectively by genotyping for 12 main HLA class-I and class-II alleles potentially 
presenting CMV-antigens. Three donor-recipient pairs from 9 experiments were 
matched respectively at HLA*A01:01, HLA*B07:02 and A*11:01, whereas no 
matches were found for the other donor-recipient pairs (Table 1). CMV-CTLs from 
donor 2, matched at HLA*A01:01 with recipient 2, did not show a positive GvHR. 
Similarly, CMV-CTLs from donor 5 matched at HLA*B07:02 with recipient 5. CMV-
CTLs from donor 8 matched with recipient 8-b in A*11:01, but gave a positive grade-
II GvHR as did the respective HLA-unmatched recipient 8-a. CMV-CTLs from donor 
6 HLA-unmatched with recipient 6-a and 6-b showed a positive grade-II GvHR (data 
not shown). Together, these results showed no difference in the incidence of GvHR 
in the skin between HLA-virus restriction matched and unmatched donor-recipient 
pairs (Fisher’s exact test: P=1.0) (SDC-Figure 5). 
In addition, CMV-CTLs harvested from the skin explant assay exhibited significantly 
lower levels of CD25 expression compared to allo-unselected-PBMCs (P=0.00096, 
P=0.0489 and P=0.0299 for CD3+, CD4+ and CD8+ T-cells, respectively) (n=4) 
(Figure 5, B).  
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To understand why CMV-CTLs led to reduced tissue damage in the skin explant 
assay, we investigated the repertoire of CD4+ and CD8+ T-cell subsets (n=4). In 2/4 
CMV-CTLs, the CD4:CD8 ratio showed a bias towards the CD8+ T-cell subset (81.77% 
and 79.10% for donor 5 and 3, respectively), whereas, the other 2 CMV-CTL lines 
(donor 6 and 8) exhibited a marked bias towards the CD4+ T-cell subset (97.80% 
and 51.70%) (data not shown). As described previously, the CMV-CTLs from donor 
6 and 8 yielded a higher GvHR-score (grade-II) at the 1x106 cell-dose, thus 
suggesting a correlation between tissue damage and an increase of CD4+ T-cells 
within the CMV-specific T-cells. The association between the frequency of the CD4+ 
T-cells and the incidence of GvHR in the skin was investigated. As expected, the 
Spearman’s test had a low power, due to n=4 (P=0.106), but a positive correlation 
coefficient (rs=0.894) was observed, which corresponded to an increasing monotonic 
trend between the percentage of the CD4+ T-cells and the incidence of GvHR 
(Figure 5-B+SDC-Figure 6). 
CMV-CTLs secreted low levels of IFN-ϒ and granzyme B  
To further support our experimental findings in the skin explant assay we measured 
IFN-ϒ and granzyme B in skin co-culture supernatants. The secretion of IFN-ϒ 
(Figure 6-A) and granzyme B (Figure 6-B) at both cell doses (5x105 and 1x106 used 
in the skin explant assay) was significantly lower for CMV-CTLs compared to the 
corresponding cell dose of unselected-PBMCs from the same CMV+donor. At the low 
and high cell dose, IFN-ϒ secretion by CMV-CTLs was found to be 4.16 [pg/ml] 
(±1.94 [pg/ml]) and 4.87 [pg/ml] (±4.50 [pg/ml]), respectively, while allo-unselected-
PBMCs resulted in 139.80 [pg/ml] (±65.23 [pg/ml]) and 326.90 [pg/ml] (±201.3 
[pg/ml]), respectively. The levels of granzyme B release were also significantly lower 
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at both cell doses, 5x105 (P=0.033) and 1x106 (P=0.0396), when compared to 
unselected-PBMCs.  
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Discussion 
One major concern of using CMV-CTLs as an anti-viral therapy in the HLA-
mismatched setting is that CMV-CTLs may recognize recipient HLA-antigens and 
induce alloreactive immune responses leading to GvHD. This study further 
elucidated the GvHR potential of HLA-mismatched third party CMV-CTLs using the 
unique human in-vitro skin explant assay40-42. We found that gamma-catch isolated 
CMV-CTLs possessed very low immunogenic capacity and gave rise to a reduced 
incidence of cutaneous GvH damage, whilst recognizing and killing target cells 
presenting the CMVpp65-antigen. 
Our results differ from other in-vitro findings which have shown the cross-reactive 
potential of virus-specific T-cells and their possibility to induce GvHD24-28. This may 
be due to prolonged culture, cloning, repeated immuno-stimulation and different sets 
of growth factors, yielding to a different pattern of T-cells and probably contributing to 
the in-vitro alloreactivity.  
Gamma-catch is based on the isolation of donor memory CD4+ and CD8+ T-cells 
responding specifically after short-term in-vitro stimulation by IFN-ϒ secretion. It is 
now applied to generate virus-specific T-cells under good manufacture practice 
conditions and has proved to be clinically effective by specifically clearing the viremia 
and restoring virus-specific immunity13. However, this cytokine-capture technology 
enriches not only T-cells, but any IFN-ϒ secreting cell, which could add to GvHD-
onset/exacerbation. We therefore tested the use of this technology for the isolation of 
virus-CTLs and examined their capacity to induce GvHR. 
After in-vitro expansion, highly enriched cell-lines were maintained, as demonstrated 
by intracellular IFN-ϒ detection following short-term re-stimulation with pp65-peptide. 
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Although the frequency of CD3+ CMV-CTLs did not change after in-vitro expansion, 
the frequency of CD4+ T-cells producing IFN-ϒ decreased to 16% upon re-
stimulation. This may be due to several reasons, such as the use of different 
techniques for the IFN-ϒ detection pre and post-expansion or the production of other 
cytokines in response to antigen re-stimulation (e.g. TNF-α) from different CD4+ T-
cell subsets. However, this question requires further investigation. 
The enriched and expanded CMV-CTLs could specifically kill pp65-loaded 
autologous PHA-blasts without inducing significant GvHR. This was supported by the 
significantly reduced allo-activation of CMV-CTLs compared to the allo-unselected-
PBMCs in the MLRs, suggesting that CMV-CTLs may have a significantly lower risk 
of initiating GvHD.  
To further analyse this, we established an in-vitro model predictive for GvHR by co-
culturing a low (5x105) and a high (1x106) CMV-CTL numbers with skin. In clinical 
protocols, the number of adoptively transferred T-cells varies, depending on the 
donor and the yield obtained after isolation without further in-vitro expansion. Several 
clinical trials have reported efficient anti-viral activity independent from the T-cell 
dose transfused. Even very low cell numbers can successfully eradicate or markedly 
reduce the virus load20,23,43,44. In our in-vitro assay, both CMV-CTL doses (5x105 and 
1x106) showed a significant reduction in GvHR compared to PBMCs (P<0.0006 and 
P<0.0001). All CMV-CTLs tested at the 5x105 T-cell doses showed a background 
reaction (grade-I GvHR) suggesting that CMV-CTLs may not react strongly against 
non-self HLA-molecules presented by haematopoietic cells and skin tissue. At 1x106 
T-cell doses, 2/9 CMV-CTL lines (donor 6 and 8) gave rise to a mild grade-II reaction 
suggesting an association between the cell dose and the severity of GvH-tissue 
damage (data not shown).  
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This is supported by significantly lower levels of IFN-ϒ and granzyme B, both directly 
involved in skin damage45, secreted by CMV-CTLs in the skin co-culture. Thus, we 
could conclude that short-term manipulated CMV-CTLs have low or no alloreactivity 
which was supported by the reduced CD25-activation in the CD3+, CD4+ and CD8+ 
subsets in the skin explant (P=0.00096, P=0.0489 and P=0.0299). The use of 
additional activation markers may further consolidate the functionality of activated 
effector T-cells. 
Analysing the composition of the CMV-CTLs showed that 2 lines contained more 
CD4+ T-cells (97.80% and 51.70%) when compared to the two non-immunogenic 
CMV-CTL lines (9.39% and 2.79%). GvH-skin injury was induced (although at a low 
level) by the CTLs with higher CD4+ content, thus suggesting an association 
between higher percentage of CD4+ T-cells in the CMV-CTLs and the incidence of 
GvHR in the skin. This was supported by a positive correlation coefficient (rs=0.894) 
and supported by previous findings46,47. Especially, the CD4+ central-memory and, to 
a lesser extent, the CD4+ naïve T-cell subpopulations were associated with allo-
immune responses, while effector-memory CD4+ T-cells was shown to not raise 
immunogenic responses in HLA-identical sibling pairs48. A strategy to deplete allo-
activated-CD38+CD4high has been further proposed to reduce the incidence of GvHD 
while maintaining the non-immunogenic T-helper cells capable of reacting against 
pathogens and maintaining the functionality of CD8+ T-cells47. Our data suggest that 
in-vitro expanded CD4+ T-cells of the central-memory type, (CD45RO+CD62L+, data 
not shown), may be involved in the recognition of allo-antigens expressed by HLA-
class-II alleles, but most importantly, that the frequency of these cells might be 
decisive in inducing GvH-skin damage.  
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The duality of virus-specific CD4+ T-cells in potentially recognizing allo-HLA-antigens 
and in playing an essential role against viruses by maintaining the CD8+ T-cell 
population49,50 or directly fighting pathogens51 needs further clarification. The 
transfusion of CMV-specific CD8+ T-cells isolated by the streptamer technology, has 
been shown to successfully eradicate viral infection by in-vivo expansion and long-
term persistence of donor CD8+ T-cells, while simultaneously recruiting the local 
CD4+ population, without signs of GvHD52. Others have reported that CMV-specific 
CD4+ T-helper cells were essential for long-term persistence of transferred donor 
CD8+ T-cell clones11,53. Furthermore, transfused CD4+ T-cell lines generated by 
repetitive CMV-antigen pulsation of dendritic cells and short in-vitro expansion were 
able to efficiently restore anti-viral immunity in 5/7 patients lacking CMV-specific T-
helper cells post-HSCT54. Clinical benefits were also observed in patients with 
refractory CMV, EBV or adenovirus infections, transfused with third-party multi-virus-
specific T-cell lines. These results showed a marked heterogeneity in the 
composition of CD4+ or CD8+ CTLs, but concomitantly a very low incidence of 
GvHD39. 
Taken together, our results and those of others, suggest that the critical role of virus-
specific CD4+ T-cell lines for alloreactivity, particularly in the HLA-mismatched 
transplantation setting, requires further investigation. Patients showing a deficit of 
both cell types may profit from the establishment of an optimal, effective and safe 
CD4+:CD8+ ratio. 
Here, we examined the alloreactive potential of CMV-CTLs specifically responding to 
pp65, which together with immediate-early protein IE-1, represent the two 
immunodominant antigenic target-proteins for CMV. Considering the importance of 
IE-1 to overcome and control CMV-infections55, the dominating role of CD4+ anti-IE1 
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proliferative responses56 and the vast repertoire of IE-1 CD4+ CTLs57, testing IE-1-
specific CD4+ T-cells for alloreactivity would further clarify the safety of CMV-CTLs 
and the effectiveness of anti-CMV immunotherapy by targeting multiple-epitopes. 
In conclusion, our pre-clinical data suggest that HLA-mismatched third party CMV-
CTLs isolated by IFN-ϒ secretion assay may effectively reduce virus infected cells 
without inducing significant GvH-tissue damage, particularly when used at a low 
dose. However, the magnitude of the CD4+ T-cell subsets within the transfused 
CMV-CTLs and their potential to induce GvHD, needs further elucidation. The 
human in-vitro GvHD model may be of value to evaluate the risk of GvHD induction 
prior to infusion of CMV-CTLs.  
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≠HLA-unmatched; =HLA-matched; NA screening results not available. * Donor 6 was paired with recipient 6-a and 6-b. * Donor 8 was paired with recipient 8-a and 8-b. 
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Table 1: Matches between HLA-alleles potentially presenting CMV-epitopes in 
donor-recipient pairs 
Figure 1: Scheme of the skin explant assay. 
Figure 2 A: Percentage of IFN-ϒ+ T-cells after stimulation with CMVpp65-antigen 
and isolation by the gamma-catch. Data are expressed as mean (±SEM) of twenty 
independent experiments (n=20). B: In-vitro expansion of CMV-CTLs after isolation 
using the gamma-catch. The graph represents CMV-CTL lines expanded with IL-2 
and autologous irradiated feeder cells for 2 to 4 weeks for each individual 
independent experiment (n=14). CMV-CTLs were expanded from a mean (±SEM) of 
3.71x105 (±9.55x104) at isolation day (day 0) to 3.95x108 (±7.61x107) after 15-28 
days in culture. C: Absolute numbers of CMV-CTL populations after in-vitro 
expansion for 2 to 4 weeks. Horizontal bars indicate the mean (±SEM) values of 
fourteen independent CMV-CTL lines (n=14). **P=0.004. 
Figure 3 Specificity of CMVpp65-CTLs after in-vitro expansion. A: Percentage of 
IFN-ϒ+ T-cells after short-term re-stimulation with pp65 of expanded T-cells. The 
detection of IFN-ϒ was performed by intracellular staining and subsequent FACS 
analysis. Data are expressed as mean (±SEM) of fourteen independent experiments 
(n=14). B: Antigen-specific cytotoxicity of CMVpp65-CTLs after in-vitro expansion 
between 2 and 4 weeks. The graph represents the specific lysis of autologous PHA-
blasts loaded and unloaded with pp65 at three different ratios, 20:1 [loaded= 93.59% 
(±1.33%); unloaded= 12.04% (±4.52%)], 5:1 [loaded= 81.10% (±8.72%); unloaded= 
19.61% (±9.71%)] and 1:1 [loaded= 50.69% (±7.80%); unloaded= 10.85% (±5.91%)], 
between CMV-CTLs (effector) and PHA-blasts (target) in three independent 
experiments (n=3). **P=0.0079, *P=0.0459.  
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Figure 4 CD25 expression of CMV-CTLs after the MLR. Percentage of CD25+ T-
cells in the autologous control: 11.04% (±2.00%) for CD3+, 17.70% (±1.50%) for 
CD4+ and 10.71% (±4.77%) for CD8+ T-cells; allogeneic unselected-PBMCs: 66.35% 
(±3.64%) for CD3+, 62.17% (±3.94%) for CD4+ and 61.94% (±7.07%) for CD8+ T-
cells and allogeneic CMV-CTLs: 17.17% (±5.90%) for CD3+, 38.20% (±5.50%) for 
CD4+ and 17.59% (±4.43%) for CD8+ T-cells. Data are expressed as mean (±SEM) 
of five independent experiments (n=5). Experiments were performed in duplicate 
where possible. ***P<0.0001, **P<0.004, ***P<0.0002.  
Figure 5 A: Assessment of the alloreactive potential of CMV-CTLs using the 
skin explant assay. Left: Histopathological grade of nine independent experiments 
(n=9); skin sections were performed in duplicate when possible. Horizontal bars 
indicate the mean ±SEM values. P<0.0006 was calculated by one-sample student t 
test which compares the mean ±SEM of the histopathology grade of alloreactive 
unselected PBMCs with the GvHD grade-I of CMV-CTL lines tested at the low cell 
dose of 5x105. ***P<0.0001. Right: Representative histological staining. Skin 
biopsies were co-cultured with A) medium only: grade-I; B) autologous-PBMCs: 
grade-I; C) 5X105 unselected-PBMCs: grade-II; d) 5X105 CMV-CTLs: grade-I; e) 
1X106 unselected-PBMCs: grade-III; F) 1X106 CMV-CTLs: grade-I. Images were 
taken by Zeiss Axio Imager 2 microscope. Scale bar= 50µm. B: CD25 activation 
and CMV-specific T-cell populations after the skin explant assay. Left: 
Percentage of CD25 positive T-cells in the autologous control: 25.89% (±5.71%) for 
CD3+, 33.48% (±5.65%) for CD4+ and 10.27% (±4.84%) for CD8+ T-cells; allogeneic-
unselected-PBMCs: 68.45% (±6.05%) for CD3+, 60.97% (±6.92%) for CD4+ and 
66.19% (±8.87%) for CD8+ T-cells and allogeneic-CMV-CTLs: 32.92% (±7.32%) for 
CD3+, 42.12% (±3.27%) for CD4+ and 34.76% (±6.67%) for CD8+ T-cells. Data are 
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expressed as mean (±SEM) of four independent experiments (n=4). Experiments 
were performed in duplicate when possible. ***P<0.0001. Right: Spearman rank 
correlation between the percentages of the CD4+ T-cell population in donors 3, 5, 6 
and 8 after the skin explant assay and the incidence of GvHR (n=4). 
Figure 6 Levels of IFN-ϒ and granzyme B released in the supernatants after co-
culture of cells with skin sections. A: Comparison of IFN-ϒ release between 
unselected-PBMCs at 5x105 and 1x106 cell doses and CMV-CTLs at 5x105 and 
1x106 cell doses. Data are expressed as mean ±SEM of six independent 
experiments (n=6). B: Comparison of granzyme B release between unselected-
PBMCs (5x105; 1x106) and CMV-CTLs (5x105; 1x106), respectively 599.90 [pg/ml] 
(±208.10 [pg/ml]); 1048.00 [pg/ml] (±372.00 [pg/ml]) and 110.50 [pg/ml] (±59.03 
[pg/ml]); 185.50 [pg/ml] (±138.40 [pg/ml]). Data are expressed as mean ±SEM of six 
independent experiments (n=6), *P=0.0330, *P=0.0396. 
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